Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LGMN | Q99538 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PPM1B | O75688 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6076980 | 0.84 | — | — | |
| SCHEMBL11464729 | 0.84 | MAPT (0.37) | ADRB2ADRB1ADRB3MAPTNPC1 | |
| SCHEMBL3998210 | 0.81 | MAPT (0.33) | ADRB2ADRB1ADRB3MAPTLGMN | |
| SCHEMBL1439554 | 0.80 | ALDH1A1 (0.44) | ADRB2ADRB1ADRB3MAPTALDH1A1 | |
| SCHEMBL18795947 | 0.79 | MAPT (0.36) | ADRB2ADRB1ADRB3MAPTLGMN | |
| SCHEMBL72855 | 0.79 | MAPT (0.51) | MAPTLGMNNPC1ALDH1A1LMNA | |
| SCHEMBL22356161 | 0.79 | LGMN (0.35) | ADRB2ADRB1ADRB3MAPTLGMN | |
| SCHEMBL4791108 | 0.79 | KMT2A (0.36) | ADRB2ADRB1ADRB3MAPTLGMN | |
| SCHEMBL707156 | 0.78 | ALDH1A1 (0.47) | ADRB2ADRB1ADRB3MAPTALDH1A1 | |
| SCHEMBL9032992 | 0.78 | ALDH1A1 (0.47) | ADRB2ADRB1ADRB3MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054279-A1 | SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-3353164-A1 | BI-HETEROARYL SUBSTITUTED 1,4-BENZODIAZEPINES AND USES THEREOF FOR THE TREATMENT OF CANCER | Janssen Pharmaceutica, N.V. (BE) | 2018-08-01 | — | — | EP | disclosed |
| EP-3353177-A1 | NEW COMPOUNDS | Janssen Pharmaceutica, N.V. (BE) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017050865-A1 | BI-HETEROARYL SUBSTITUTED 1,4-BENZODIAZEPINES AND USES THEREOF FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017050864-A1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-30 | — | — | WO | disclosed |
| EP-3122742-A1 | QUINOXALINE DERIVATIVES USEFUL AS FGFR KINASE MODULATORS | Astex Therapeutics Ltd (GB) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015144803-A1 | QUINOXALINE DERIVATIVES USEFUL AS FGFR KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-01 | — | — | WO | disclosed |
| US-9078874-B2 | Composition and method for treating cognitive impairments in down syndrom subjects | Centre National de la Recherche Scientifique—CNRS (FR) | 2015-07-14 | — | — | US | disclosed |
| EP-2470176-B1 | COMPOSITION AND METHOD FOR TREATING COGNITIVE IMPAIRMENTS IN DOWN SYNDROM SUBJECTS | CENTRE NAT RECH SCIENT (FR) | 2014-12-10 | — | — | EP | disclosed |
| EP-2332909-B1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| WO-2004014922-A1 | 3-(CARBONYL) 1H-INDAZOLE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
| US-5686461-A | INHIBITION OF NMDA INDUCED CONVULSIONS | GLAXO WELLCOME S.P.A. (IT) | 1997-11-11 | — | — | US | disclosed |
| US-5576312-A | 1-azatricyclo[7.2.0.03,8 ]undec-2-ene-2-carboxylates as antibacterial compounds | GLAXO SPA (IT) | 1996-11-19 | — | — | US | disclosed |
| EP-0699186-A1 | INDOLE DERIVATIVES AS ANTAGONISTS OF EXCITATORY AMINO ACIDS | GLAXO S.p.A. (IT) | 1996-03-06 | — | — | EP | disclosed |
| EP-0656899-A1 | CONDENSED CARBAPENEM DERIVATIVES | GLAXO S.p.A. (IT) | 1995-06-14 | — | — | EP | disclosed |
| US-5374649-A | Nervous system disorders | GLAXO S.P.A. (IT) | 1994-12-20 | — | — | US | disclosed |
| US-5374648-A | Nervous system disorders | GLAXO S.P.A. (IT) | 1994-12-20 | — | — | US | disclosed |
| WO-1994020465-A1 | INDOLE DERIVATIVES AS ANTAGONISTS OF EXCITATORY AMINO ACIDS | GLAXO S.P.A. (IT) | 1994-09-15 | — | — | WO | disclosed |
| WO-1994005666-A1 | CONDENSED CARBAPENEM DERIVATIVES | GLAXO S.P.A. (IT) | 1994-03-17 | — | — | WO | disclosed |
| EP-0568136-A1 | Indole-2-carboxylic acid derivatives | GLAXO S.p.A. (IT) | 1993-11-03 | — | — | EP | disclosed |